MARKET OUTLOOK

Obesity is arguably the most pressing public health issue in the United States with its chronic progression that is associated with both type 2 diabetes and adverse cardiovascular health. Current therapies have struggled to achieve meaningful weight loss without compromising the overall risk-benefit of intervention. Following a series of high profile market withdrawals, the barren obesity drug landscape saw a relative rush of new treatment options come to market from 2012 to 2017. In this report, endocrinologists reveal how the current generation of antiobesity drugs compare with one another and what attributes the next generation of these agents will need to crack this medically important and potentially lucrative market.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for obesity?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for obesity?
  • What are the prevailing areas of unmet need and opportunity in obesity?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists for a hypothetical new obesity drug?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European endocrinologists fielded in December 2018.

Key companies: Novo Nordisk, Eisai, Vivus, Orexigen Therapeutics, Pernix Therapeutics.

Key drugs: Saxenda, Qsymia, Contrave/Mysimba, Belviq.

Table of contents

  • Detailed, Expanded Analysis (US/EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Obesity/Overweight
      • Key Findings: Unmet Need in Obesity/Overweight and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Obesity/Overweight Market and Emerging Therapy Insights
        • Opportunity: An Agent That Provides Improved and Sustained Weight-Loss Efficacy
        • Opportunity: Antiobesity Agent That Improves Lipid Profile and Glycemic Control
        • Opportunity: An Agent with Robust Outcomes Data and Long-Term Safety
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Obesity/Overweight Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
        • Scenario 3
    • Appendix
      • Bibliography

Author(s): Rameshwar Prajapati, Ph.D., M.S. (Pharm.)

Rameshwar Prajapati, (Pharm.), is a business insights analyst in Decision Resources Group’s cardiovascular, metabolic, renal, and hematologic disorders team, focusing primarily on obesity. In this role, his main function is to perform primary and secondary research related to obesity and its treatment, as well as providing insights and assessments for the major pharmaceutical markets regarding weight loss medications. Rameshwar holds a bachelor’s degree in pharmacy from Dr. Gour University, Sagar, India. He obtained his master’s and doctorate degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Nagar, India. Rameshwar also received a German Academic Exchange Service (DAAD) fellowship to conduct his research on P-glycoprotein at the University of Bonn, Germany.


Related Reports

Obesity/Overweight | Epidemiology | Epidemiology Dashboard

DRG Epidemiology's coverage of obesity/overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report diagnosed prevalence of obesity/...

View Details

Obesity/Overweight | Landscape & Forecast | Disease Landscape & Forecast

Obesity is a significant public health concern and a growing epidemic in the G7 countries. The body of evidence highlighting the physical and economic impact of obesity on society is steadily inc...

View Details

Obesity/Overweight | Epidemiology | Americas

DRG Epidemiology's coverage of obesity/overweight comprises epidemiological estimates of key patient populations across the major mature pharmace...

View Details

Obesity/Overweight | Epidemiology | Middle East & Africa

DRG Epidemiology's coverage of obesity/overweight comprises epidemiological estimates of key patient populations across the major mature pharmace...

View Details